TRANSFORM-HF Ancillary Mechanistic Study

Inova Health Care Services150 enrolled

Overview

Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.

Patients who are enrolling in the TRANSFORM-HF study or being prescribed Torsemide or Furosemide at hospital discharge will provide blood and urine at the time of study enrollment (within 72 hours of hospital discharge) and at 90 days (+/- one week) after hospital discharge.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Heart Failure

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participation in the TRANSFORM-HF trial or prescription of Torsemide or Furosemide * Willing to provide blood and urine sample at enrollment and follow-up Exclusion Criteria: * Inability or unwillingness to comply with the study requirements

Locations (9)

Yale University School of Medicine

New Haven, Connecticut, United States

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Baltimore VA

Baltimore, Maryland, United States

University of Minnesota

Outcomes

Primary Outcomes

Differences in proteomic protein clusters between treatment groups

How the biomarkers are different between groups

Time frame: baseline

Differences in trajectories of protein clusters between treatment groups

How the protein clusters change over time from baseline to 90 days

Time frame: 90 days

Secondary Outcomes

Differences in single biomarkers and biomarker trajectories between treatment groups

How the biomarkers are different between groups at baseline and how the biomarkers change over time from baseline to 90 days

Time frame: baseline and 90 days

Differences in urinary protein levels between treatment groups

How the in urinary protein levels are different between patient prescribed Torsemide vs Furosemide

Time frame: baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.